Abstract

The conceptual appeal of “pay-for-performance” or “risk-sharing” agreements is understandable. The agreements offer an innovative payment model under which payers reimburse manufacturers on the basis of health outcomes achieved rather than products provided. In theory, the effects of these arrangements can be far-reaching, promising to improve population health and drive systemwide efficiencies.